Hansa Biopharma AB
Clinical trials sponsored by Hansa Biopharma AB, explained in plain language.
A biopharmaceutical company developing immunomodulatory therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could unlock kidney transplants for sensitized kids Results expected Feb 2027 (estimated)
-
Breakthrough drug may give hope to kidney patients rejected for transplant
Disease control CompletedThis study tested a drug called imlifidase in 113 highly sensitized kidney patients who had a positive crossmatch against a deceased donor. The drug was given before transplant to reduce the risk of rejection. The main goal was to see how many patients still had a working kidney …
Phase 3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Breakthrough drug could open door to kidney transplants for 'Impossible' patients
Disease control CompletedThis phase 3 trial tested a drug called imlifidase in 64 highly sensitized kidney transplant patients who had almost no chance of finding a compatible donor. The drug breaks down harmful antibodies, allowing a transplant from a donor that would normally be rejected. The study mea…
Phase 3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC